We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > HNSCC

News List

AstraZeneca's head and neck cancer treatment Imfinzi falls flat in Phase III trials pharmafile
December 10, 2018
AstraZeneca’s immunotherapy treatment Imfinzi has failed to meet its primary goal in treating head and neck cancer in the Phase III EAGLE trial.
First-line Keytruda shows better overall survival in head & neck cancer pharmafile
November 01, 2018
MSD’s Keytruda (pembrolizumab) made an impact at the European Society for Medical Oncology 2018 Congress as the company unveiled new Phase 3 data into its efficacy in the first-line treatment...
MSD’s Keytruda hits rare snag, floundering in confirmatory trial pharmafile
July 26, 2017
Since the PD-1/PD-L1 immunotherapies have hit the market, they have revolutionised cancer care for many patients yet, with the science not completely understood

Previous page 1 2 Next page